HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA, Dr. Bronner’s Champion Bill To Legalize U.S. Industrial Hemp Production

This article was originally published in The Rose Sheet

Executive Summary

New legislation from Rep. Ron Paul, R.-Texas, would legalize the cultivation and processing of industrial hemp, opening the door for U.S. farmers to compete in what could be a “very profitable” market and enabling U.S. cosmetics manufacturers to leverage the plant’s seed and oil without relying on foreign imports.

You may also be interested in...



In Brief

The European Commission has amended EU REACH chemicals law so that SMEs pay less in registration fees, while larger companies pay more. More news in brief.

Dr. Bronner’s CEO Protests Federal Industrial Hemp Policy In D.C.

Advocating for change to the federal government’s hemp policy, CEO David Bronner of Dr. Bronner’s Magic Soaps, which uses hemp oil in its cleansing and skin-care products, locked himself in a steel cage in front of the White House June 11 and harvested industrial hemp plants before being arrested.

Natural Products Expo West In Brief

W.S. Badger chose to launch sunscreens and debut new labels at Natural Products Expo West in Anaheim, Calif., March 9-11, while Skin Nutrition took the opportunity to present its superfood skin-care line. Dr. Bronner’s Magic Soaps’ President David Bronner promoted the firm’s most recent cause at the show, anti-GMOs, by walking the halls in a biohazard suit.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel